Resultados de la búsqueda 351-360 of 17777 for Omega-3

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns of ...

2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients will receive VSL#3® 450B sachets probiotics, which will be provided as part of this trial, at least 3 days but preferably 1-2 weeks prior to starting ...

3. Mayo Clinic Cancer Physician Update - March 2025

   Page 1.

4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns of ...

5. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

   Patients will receive VSL#3® 450B sachets probiotics, which will be provided as part of this trial, at least 3 days but preferably 1-2 weeks prior to starting ...

6. Nutrición y comida saludable - Mayo Clinic

   Omega-3 del pescado · Peso insuficiente: suma libras de manera saludable · Probióticos y prebióticos · Problemas en el pícnic: sodio elevado · Programación de ...

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be randomized to one of three arms: A) current COG recommended high-risk therapy including ...

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients will receive VSL#3® 450B sachets probiotics, which will be provided as part of this trial, at least 3 days but preferably 1-2 weeks prior to starting ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This is a prospective, pilot, single arm study to evaluate the incidence of IIC in patients with solid malignancies receiving VSL#3 and ICIs. Given the fact ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a prospective, pilot, single arm study to evaluate the incidence of IIC in patients with solid malignancies receiving VSL#3 and ICIs. Given the fact ...